The most tolerable antibody is the anti-NOTCH1 mAb OMP-52M51 (Brontictuzumab), which has been evaluated in clinical studies for refractory tumors and R/R lymphoid malignancies (NCT01778439) [53], including T-ALL (NCT01703572) [8]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.